Retrospective Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2023; 15(11): 1925-1935
Published online Nov 15, 2023. doi: 10.4251/wjgo.v15.i11.1925
Application of sintilimab combined with anlotinib hydrochloride in the clinical treatment of microsatellite stable colorectal cancer
Rui Feng, De-Xin Cheng, Xiao-Chen Chen, Liu Yang, Hao Wu
Rui Feng, De-Xin Cheng, Department of Interventional Medicine, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310000, Zhejiang Province, China
Xiao-Chen Chen, Liu Yang, Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310000, Zhejiang Province, China
Hao Wu, Department of Vascular Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310000, Zhejiang Province, China
Author contributions: Feng R and Wu H designed the study; Cheng DX, Chen XC, and Yang L performed the experiments; Feng R, Cheng DX, and Chen CX analyzed the data; Feng R wrote the manuscript; Wu H reviewed and revised the manuscript; All authors read and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by Ethics Committee of Zhejiang Provincial People’s Hospital.
Informed consent statement: The data used in this study were not involved in the patients’ privacy information, so the informed consent was waived by the Ethics Committee of Zhejiang Provincial People’s Hospital. All data obtained, recorded, and managed was only used for this study, without any harm to the patients.
Conflict-of-interest statement: All the authors report having no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hao Wu, MM, Attending Doctor, Department of Vascular Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou 310000, Zhejiang Province, China. wuhao89899@163.com
Received: September 7, 2023
Peer-review started: September 7, 2023
First decision: September 15, 2023
Revised: September 23, 2023
Accepted: September 27, 2023
Article in press: September 27, 2023
Published online: November 15, 2023
Core Tip

Core Tip: In the treatment of microsatellite stable (MSS) colorectal cancer (CRC), preclinical and early clinical studies have shown that monoclonal antibody therapy and anlotinib hydrochloride has the potential to enhance antitumor immune responses and inhibit tumor growth in MSS CRC. By targeting both the tumor microenvironment and the signaling pathways crucial for cancer cell survival, this dual approach may provide a synergistic effect, leading to improved treatment response and prolonged survival in patients with MSS-CRC. In summary, the combination of monoclonal antibody therapy and hydrochloride anlotinib may offer a new treatment option for patients with MSS CRC.